Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
$5.39
-5.4%
$7.06
$5.32
$18.75
$205.87M1.43460,149 shs310,100 shs
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$9.69
-7.8%
$15.45
$9.45
$29.56
$738.73M2.23911,426 shs1.49 million shs
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$19.19
-5.1%
$22.71
$12.30
$26.55
$777.25M0.58186,614 shs288,935 shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$5.58
-6.4%
$8.36
$5.49
$14.45
$817.37M1.141.32 million shs1.90 million shs
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
0.00%-14.72%-23.98%-33.87%-58.92%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
0.00%-20.25%-31.03%-50.84%-33.58%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
0.00%-10.58%-17.67%-6.48%+48.41%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
0.00%-16.72%-30.86%-25.60%-42.41%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
2.5281 of 5 stars
3.53.00.00.02.12.50.6
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
1.73 of 5 stars
4.40.00.00.02.50.80.0
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
3.6818 of 5 stars
0.85.01.71.13.13.32.5
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
3.4667 of 5 stars
4.42.00.00.02.03.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
3.00
Buy$25.75377.74% Upside
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
2.83
Moderate Buy$30.88218.70% Upside
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
1.50
Reduce$21.009.43% Upside
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.83
Moderate Buy$35.67539.19% Upside

Current Analyst Ratings Breakdown

Latest ITOS, NRIX, VIR, and PAHC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/2/2025
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
3/17/2025
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
3/17/2025
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$16.00
3/6/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$19.00 ➝ $17.00
3/6/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$22.00 ➝ $15.00
3/6/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
3/5/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$25.00
2/28/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$26.00 ➝ $31.00
2/28/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$110.00 ➝ $110.00
2/27/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
2/10/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderweight ➝ Underweight$20.00 ➝ $22.00
(Data available from 4/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
$35M5.88N/AN/A$16.08 per share0.34
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$54.55M13.54N/AN/A$7.44 per share1.30
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$1.11B0.70$1.77 per share10.87$6.09 per share3.15
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$63.71M12.01N/AN/A$11.82 per share0.47
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-$112.64M-$3.31N/AN/AN/AN/A-20.11%-17.50%5/9/2025 (Estimated)
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$193.57M-$2.89N/AN/AN/A-354.85%-53.65%-38.59%4/9/2025 (Estimated)
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$2.42M$0.4839.989.140.451.75%25.35%6.21%5/6/2025 (Estimated)
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$615.06M-$3.82N/AN/AN/A-678.40%-36.71%-31.00%5/1/2025 (Estimated)

Latest ITOS, NRIX, VIR, and PAHC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.83N/AN/AN/A$8.59 millionN/A
4/9/2025N/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$0.72N/AN/AN/A$12.78 millionN/A
3/5/2025Q4 2024
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-$1.14-$1.01+$0.13-$1.01N/AN/A
2/26/2025Q4 2024
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.85-$0.76+$0.09-$0.76$8.14 million$12.37 million
2/5/2025Q2 2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.40$0.54+$0.14$0.08$292.26 millionN/A
1/28/2025Q4 2024
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$0.67-$0.75-$0.08-$0.75N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
N/AN/AN/AN/AN/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/AN/AN/AN/AN/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.482.50%N/A100.00%N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/AN/AN/AN/AN/A

Latest ITOS, NRIX, VIR, and PAHC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/4/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
quarterly$0.122.18%3/5/20253/5/20253/26/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
N/A
14.80
14.80
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/A
6.46
6.46
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
2.99
3.20
1.37
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/A
8.94
8.94

Institutional Ownership

CompanyInstitutional Ownership
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
97.16%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
99.34%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
65.32%

Insider Ownership

CompanyInsider Ownership
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
12.50%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
7.20%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
50.07%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
15.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
9038.19 million31.97 millionOptionable
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
30076.24 million70.42 millionOptionable
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
1,86040.50 million20.22 millionOptionable
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
580137.14 million116.24 millionOptionable

Recent News About These Companies

Stock Movers: Moderna, Tesla, Canada Goose
Vir Biotechnology enrolls first patient in ECLIPSE program
Barclays Remains a Buy on Vir Biotechnology (VIR)
Vir Biotechnology price target raised to $31 from $26 at Barclays
Q4 2024 Vir Biotechnology Inc Earnings Call

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
iTeos Therapeutics stock logo

iTeos Therapeutics NASDAQ:ITOS

$5.39 -0.31 (-5.44%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$5.39 0.00 (0.00%)
As of 04/4/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Nurix Therapeutics stock logo

Nurix Therapeutics NASDAQ:NRIX

$9.69 -0.82 (-7.80%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$9.78 +0.09 (+0.88%)
As of 04/4/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$19.19 -1.03 (-5.09%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$19.20 +0.00 (+0.03%)
As of 04/4/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Vir Biotechnology stock logo

Vir Biotechnology NASDAQ:VIR

$5.58 -0.38 (-6.38%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$5.70 +0.13 (+2.24%)
As of 04/4/2025 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.